LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026)
LENZ Therapeutics (LENZ) reported Free Cash Flow of -$33.6 million for Q1 2026, down 107.93% year-over-year from $423.5 million in Q1 2025, and down 1.62% on a QoQ basis from -$33.1 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Free Cash Flow data on file, last reported at -$33.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 107.93% year-over-year to -$33.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$87.4 million (down 68.75% YoY) and the FY2025 annual result came in at -$70.0 million, down 17.46% from the prior year.
- Free Cash Flow eased to -$33.6 million in Q1 2026 per LENZ's latest filing, from -$33.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.0 million in Q3 2025 and bottomed at -$33.6 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$16.2 million (2025), against an average of -$18.7 million.
- The widest annual swing landed in 2024, when Free Cash Flow jumped 55.89%; it then slumped 257.48% in 2025.
- Tracing LENZ's Free Cash Flow over 5 years: stood at -$23.4 million in 2022, then climbed by 10.58% to -$21.0 million in 2023, then jumped by 55.89% to -$9.2 million in 2024, then tumbled by 257.48% to -$33.1 million in 2025, then retreated by 1.62% to -$33.6 million in 2026.
- Per Business Quant, the three latest LENZ Free Cash Flow figures stand at -$33.6 million (Q1 2026), -$33.1 million (Q4 2025), and -$9.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -33.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.60 Mn |
| Mar 31, 2026 | -33.60 Mn |
| Dec 31, 2025 | -33.06 Mn |
| Dec 31, 2025 | -33.06 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Sep 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Sep 30, 2024 | -10.48 Mn |
| Jun 30, 2024 | -15.93 Mn |
| Jun 30, 2024 | -15.93 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Dec 31, 2023 | -20.97 Mn |
| Dec 31, 2023 | -20.97 Mn |
| Sep 30, 2023 | -13.09 Mn |
| Sep 30, 2023 | -13.09 Mn |
| Jun 30, 2023 | -13.55 Mn |
| Jun 30, 2023 | -13.55 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Dec 31, 2022 | -23.45 Mn |
| Dec 31, 2022 | -23.45 Mn |
| Sep 30, 2022 | -23.13 Mn |
| Sep 30, 2022 | -23.13 Mn |
| Jun 30, 2022 | -23.48 Mn |
| Jun 30, 2022 | -23.48 Mn |
| Mar 31, 2022 | -24.51 Mn |
| Mar 31, 2022 | -24.51 Mn |
| Dec 31, 2021 | -16.57 Mn |
| Dec 31, 2021 | -16.57 Mn |
| Sep 30, 2021 | -19.05 Mn |
| Sep 30, 2021 | -19.05 Mn |
| Jun 30, 2021 | -14.55 Mn |
| Jun 30, 2021 | -14.55 Mn |
| Mar 31, 2021 | -8.42 Mn |
| Mar 31, 2021 | -8.42 Mn |
| Dec 31, 2020 | -5.88 Mn |
| Dec 31, 2020 | -5.88 Mn |
| Sep 30, 2020 | -3.05 Mn |
| Sep 30, 2020 | -3.05 Mn |